Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of JNJ-26070109 in healthy volunteers
NL-OMON30846Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-26070109 in gastroesophageal reflux disease (GERD) (9 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Safety and tolerability, Pharmacokinetics and 3 more. Started Apr 2007; status: active, not recruiting.
02
Drugs
JNJ-26070109
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NL-OMON30846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30846.